NEW YORK (GenomeWeb) – Cepheid has signed a non-exclusive distribution agreement with Henry Schein Medical — the US health care products and services business of Henry Schein, Inc. — for the GeneXpert molecular diagnostics system and associated tests, the company announced today. Terms of the deal were not disclosed
The agreement focuses on the GeneXpert and test portfolio, including an influenza and respiratory syncytial virus assay that was CLIA waived in December. It expands distribution of the GeneXpert platform and menu of 17 Xpert tests beyond the traditional hospital lab space, according to Cepheid.
"Our relationship with Henry Schein opens an immediate opportunity for GeneXpert System placements in more than 10,000 moderately complex labs outside the hospital," said Cepheid's Chief Medical and Technology Officer David Persing in a statement.
The non-acute care lab market reached by the Henry Schein distribution network includes physicians’ office labs, women’s health clinics, urgent care facilities, community health centers, correctional facilities, student health centers, STD clinics, long-term care facilities, and reference labs.
Henry Schein will also distribute Cepheid's point-of-care molecular platform, the GeneXpert Omni, subject to US Food and Drug Administration approval of the new platform and associated tests. The firm anticipates launching the Omni in late 2016, with Henry Schein providing access to more than 100,000 CLIA-waived physician office laboratories, Persing added.